Organization
Nektar Therapeutics
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Nektar Therapeutics
... closing at $$47.25. The stock is down about 9 percent this year. Nektar Therapeutics reported Wednesday that it had second-quarter net income of $971.5 million ...
... be available throughout 2019;Presented encouraging preclinical data on combination therapy of BXCL701, Nektar Therapeutics' NKTR-214 and an anti-PD1 agent in pancreatic cancer at the 2018 ...
... Today, Nektar Therapeutics and Bristol-Myers Squibb (BMS) announced a record-breaking partnership deal worth up ...
... Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on ...
... Biopharmaceutical company Nektar Therapeutics (Nasdaq:NKTR) said on Monday that it has successfully filed its New Drug ...
... Moleculin Biotech, Inc. (NASDAQ:MBRX), OPKO Health, Inc. (NASDAQ:OPK), Celgene Corporation (NASDAQ:CELG), Nektar Therapeutics (NASDAQ:NKTR), BioTime, Inc. (NYSE:BTX). Moleculin Biotech, Inc. (NASDAQ:MBRX)BREAKING NEWS:Moleculin Biotech, a clinical ...
... Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) ...
... all current investors, traders, and shareholders of Fidelity Southern Corporation (NASDAQ:LION), Nektar Therapeutics (NASDAQ:NKTR), CSG Systems International, Inc. (NASDAQ:CSGS), Ellington Financial LLC (NYSE:EFC), NBT Bancorp ...
... in the quarter, which includes a $1.1 billion charge resulting from the Nektar collaboration in the second quarter of 2018.The effective tax rate was 26.1% ...
Subscribe now for full coverage on Nektar Therapeutics
Start My Free Trial